A Phase 3 interventional study of belimumab in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 110 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-05.
Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 5th largest by enrollment, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 6th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 738 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc., a GSK Company is the lead sponsor of 13 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 5th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2008, is one of 10 in phase 3, and was the 6th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
This is a long-term continuation study to provide continuing treatment to subjects with SLE.
This trial is a long-term continuation study to provide continuing treatment to subjects with System Lupus Erythematosus (SLE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 mg/kg dose of belimumab given IV every 28 days.
Drug: belimumab
10 mg/kg dose of belimumab given IV every 28 days.
Drug: belimumab
Recombinant, fully human, monoclonal antibody Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.
Also known as: LymphoStat-B™, HGS1006
Number of Participants With Adverse Events (AE)
An adverse event is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example: increase in frequency or severity) of preexisting conditions. Participants with incidences of any event at any time post-baseline are presented by yearly interval. Only treatment-emergent AEs are summarized.
Time frame: Up to 9 years
AE Rates by System Organ Class (SOC) During the Study
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent AEs are summarized. The event rate of an AE was calculated as the number of events per 100 participant years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
Time frame: Up to 9 years
Number of Participants With Serious Adverse Events (SAE)
An adverse event resulting in death, is life threatening (ie, an immediate threat to life), inpatient hospitalization, prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or any other situation which is medically important is categorized as SAE. Only treatment-emergent AEs are summarized.
Time frame: Up to 9 years
SAE Rates by SOC During the Study
SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The event rate of an SAE was calculated as the number of events per 100 participant years. Participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by 365). Participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
Time frame: Up to 9 years
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point
Time frame: Baseline and up to 9 years
Change From Baseline in Platelets (Plt), Lymphocytes (Lymp), Leukocytes (Leu), Eosinophils (Eos), Basophils (Baso), Monocytes (Mono), Neutrophils (Neu), Neutrophils Band Form (NeuBF), Neutrophils Segmented (NeuS) at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Plt, Lymp, Leu, Eos, Baso, Mono, Neu, NeuBF, and NueS are summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Hemoglobin (Hg) at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Hg is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Hematocrit at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks). Change from Baseline in Hematocrit is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Erythrocytes (Eryth) at the Indicated Time Points
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Erythrocytes is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Calcium (Ca), Carbon Dioxide (CO2), Chloride, Magnesium (Mg), Phosphate (Phos), Potassium (K), Sodium (Na) at the Indicated Time Points
Electrolytes parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 electrolytes parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ca,CO2, Chloride, Mg, Phos, K and Na were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Blood Urea Nitrogen/Creatinine (BUN/Cr) at the Indicated Time Points
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN/Cr is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Baseline and up to 9 years
Change From Baseline in Albumin (Alb) and Protein (Pro) at the Indicated Time Points
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Alb and Protein were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in BUN and Glucose at the Indicated Time Points
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN and Glucose were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Creatinine (Cr) and Urate at the Indicated Time Points
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Cr and Urate were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels
Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in ALT, ALP, AST, GGT and LDH were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Bilirubin (Bili) Levels
Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Bili were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Change From Baseline in Immunoglobulin G (IgG) Levels
Immunoglobulin (Ig) parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 Ig parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ig G were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
Time frame: Baseline and up to 9 years
Number of Participants With Immunogenic Response by Year
Immunogenic response was analyzed using serum samples for anti-belimumab antibody measurements in MITT population. Categories of response are Negative, Transient Positive (+) means single + response that does not occur at the final assessment, and Persistent + means + response that occurs at least 2 consecutive assessments or a single result at the final assessment. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to 9 years
Number of Participants With IgG Values Below the Lower Limit of Normal by Year
Blood samples were collected to evaluate IgG levels at Baseline and at Weeks 12, 24 and 48 during Year 1. From Year 2-9, IgG was evaluated at Week 24 and 48 ; Exit visit and at follow-up visit (up to 8 weeks post last infusion). Number of participants with IgG immunoglobulin values below the LLN at each one year interval are presented. Baseline includes Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. If a participant had more than one response within a year, then the last response within the year interval (usually the Week 48 assessment) was summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to 9 years
Number of Participants With Shifts From Baseline in Prednisone and Other Steroids Dose by Visit
Participants who had improving SLE disease activity for at least 8 weeks, at the investigator's discretion, the steroid dose was reduced by reduction to 7.5 mg/day. If the participant continued to have stable or improving disease activity after 4 weeks on a reduced dose, then the investigator considered reducing the dose again. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. Number of participants with shifts from Baseline total daily dose category by visit is summarized.
Time frame: Up to 9 years
Number of Participants With Any SLICC/ ACR Damage Index Worsening (Change > 0) From Baseline by Visit
The SLICC/ACR Damage Index was assessed every 48 weeks and at the exit visit as a measure of disease activity. It was developed to assess the accumulated damage since the onset of the disease. The number of participants with worsening in their SLICC/ACR Damage Index score compared with Baseline have been presented. Worsening was defined as a change in score (post-Baseline visit score - Baseline score) \> 0. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. For years in which a participant was withdrawn from the study, the exit visit assessment was used in place of the Week 48 assessment for the year. This value was not carried forward through later years. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to 9 years
This was a multi-center, continuation trial of belimumab and was conducted at 115 centers in 28 countries. Participants with Systemic Lupus Erythematosus (SLE), who had completed the Phase 3 HGS1006-C1056 or HGS1006-C1057 trial or participants who had previously received subcutaneous belimumab in Protocol HGS1006-C1070 were included in this trial.
| Milestone | Belimumab 10mg/kg IV |
|---|---|
| Started | 735 |
| Completed | 368 |
| Not completed | 367 |
| Withdrew: Adverse event | 69 |
| Withdrew: Lack of efficacy | 6 |
| Withdrew: Lost to follow-up | 22 |
| Withdrew: Non-compliance with study drug | 13 |
| Withdrew: Other pregnancy | 37 |
| Withdrew: Sponsor decision | 14 |
| Withdrew: Withdrew consent | 4 |
| Withdrew: Hip replacement surgery | 1 |
| Withdrew: Involved in clinical research | 3 |
| Withdrew: Participant hospitalized | 1 |
| Withdrew: Participant travelled overseas | 2 |
| Withdrew: Death of patient | 1 |
| Withdrew: Other physician decision | 1 |
| Withdrew: Not committed to contraception | 1 |
| Withdrew: Participant received medication | 1 |
| Withdrew: Physician decision | 36 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Withdrawal by subject | 151 |
An adverse event is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example: increase in frequency or severity) of preexisting conditions. Participants with incidences of any event at any time post-baseline are presented by yearly interval. Only treatment-emergent AEs are summarized.
| Participants | Belimumab 10mg/kg IV |
|---|---|
| Any-time post Baseline,n=735 | 706 |
| Year 0-1,n=735 | 617 |
| Year 1-2 ,n =701 | 502 |
| Year 2-3, n= 620 | 441 |
| Year 3-4,n= 514 | 344 |
| Year 4-5,n= 442 | 261 |
| Year 5-6, n =345 | 181 |
| Year 6-7, n= 219 | 92 |
| Year 7-8, n = 65 | 26 |
| Year 8 plus,n = 6 | 3 |
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent AEs are summarized. The event rate of an AE was calculated as the number of events per 100 participant years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
| Adverse events per 100 participant years | Belimumab 10mg/kg IV |
|---|---|
| Infections and infestations | 101.8 |
| Gastrointestinal disorders | 32.8 |
| Musculoskeletal and connective tissuedisorder | 32.8 |
| Nervous system disorders | 22.6 |
| Skin and subcutaneous and tissue disorders | 22.5 |
| Respiratory,thoracic and mediastinal disorder | 14.9 |
| Vascular disorders | 13.3 |
| General disorders and administration sitecondition | 11.8 |
| Injury, poisoning andprocedural complications | 11.5 |
| Blood and lymphatic system disorders | 7.5 |
| Eye disorders | 6.6 |
| Reproductive system and breast disorders | 6.4 |
| Investigations | 5.8 |
| Psychiatric disorders | 5.6 |
| Renal and urinary and disorder | 5.3 |
| Metabolism and nutrition disorder | 3.6 |
| Cardiac disorders | 3.0 |
| Ear and labyrinth disorder | 2.4 |
| Neoplasms benign,malignant andunspecified | 2.2 |
| Hepatobiliary disorders | 1.8 |
| Immune system disorder | 1.2 |
| Endocrine disorders | 1.0 |
| Social circumstances | 0.7 |
| Congenital, familial and genetic disorders | 0.1 |
| Pregnancy, puerperium and perinatal conditions | 0.1 |
| Product Issues | 0.1 |
An adverse event resulting in death, is life threatening (ie, an immediate threat to life), inpatient hospitalization, prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or any other situation which is medically important is categorized as SAE. Only treatment-emergent AEs are summarized.
| Participants | Belimumab 10mg/kg IV |
|---|---|
| Any post-Baseline,n=735 | 231 |
| Year 0-1,n=735 | 78 |
| Year 1-2,n = 701 | 58 |
| Year 2-3,n = 620 | 66 |
| Year 3-4,n= 514 | 44 |
| Year 4-5 ,n= 442 | 27 |
| Year 5-6,n=345 | 16 |
| Year 6-7,n= 219 | 11 |
| Year 7-8,n= 65 | 1 |
| Year 8 plus,n= 6 | 0 |
SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The event rate of an SAE was calculated as the number of events per 100 participant years. Participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by 365). Participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
| Adverse events per 100 participant years | Belimumab 10mg/kg IV |
|---|---|
| Infections and infestations | 5.1 |
| Blood and lymphatic system disorders | 1.0 |
| Musculoskeletal and connective tissue disorder | 1.0 |
| Gastrointestinal disorders | 1.0 |
| Renal and urinary disorders | 0.8 |
| Vascular disorders | 0.8 |
| Injury, poisoning andprocedural complications | 0.8 |
| General disorders and administration sitecondition | 0.6 |
| Nervous system disorders | 0.6 |
| Respiratory, thoracic and mediastinal disorder | 0.5 |
| Cardiac disorders | 0.5 |
| Skin and subcutaneous tissue disorders | 0.5 |
| Neoplasms benign, malignant and unspecified | 0.4 |
| Reproductive system and breast disorder | 0.4 |
| Psychiatric disorders | 0.4 |
| Hepatobiliary disorders | 0.3 |
| Metabolism and nutrition disorders | 0.1 |
| Pregnancy, puerperium and perinatal condition | 0.1 |
| Endocrine disorders | 0.1 |
| Immune system disorders | 0.1 |
| Ear and labyrinth disorders | 0.1 |
| Eye disorders | 0.1 |
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point
| Seconds | Belimumab 10mg/kg IV |
|---|---|
| Year1,Week4,APTT,n=208 | 0.7 ± 5.27 |
| Year1,Week12,APTT,n=208 | 2.1 ± 12.31 |
| Year1,Week24,APTT,n=686 | 0.1 ± 9.10 |
| Year1,Week36,APTT,n=193 | 2.5 ± 5.75 |
| Year1,Week48,APTT,n=666 | 0.8 ± 9.48 |
| Year2,Week24,APTT,n=625 | 2.7 ± 9.74 |
| Year2,Week48,APTT,n=572 | 2.7 ± 9.66 |
| Year3,Week24,APTT,n=521 | 3.4 ± 10.01 |
| Year3,Week48,APTT,n=470 | 3.9 ± 11.41 |
| Year4,Week24,APTT,n=422 | 3.5 ± 10.70 |
| Year4,Week48,APTT,n=412 | 4.2 ± 6.63 |
| Year5,Week24,APTT,n=383 | 4.1 ± 10.71 |
| Year5,Week48,APTT,n=349 | 3.5 ± 6.35 |
| Year6,Week24,APTT,n=292 | 3.8 ± 6.58 |
| Year6,Week48,APTT,n=277 | 4.3 ± 7.91 |
| Year7,Week24,APTT,n=177 | 6.4 ± 14.52 |
| Year7,Week48,APTT,n=131 | 4.1 ± 6.23 |
| Year8,Week24,APTT,n=52 | 5.6 ± 7.54 |
| Year8,Week48,APTT,n=13 | 4.2 ± 3.98 |
| Year9,Week24,APTT,n=6 | 5.0 ± 6.39 |
| Year9,Week48,APTT,n=1 | 9.0 ± NA |
| Exit, APTT,n=586 | 3.2 ± 10.71 |
| 8 Week,Follow up,n=524 | 3.4 ± 8.14 |
| Year1,Week4,PT,n=205 | -0.22 ± 5.139 |
| Year1,Week12,PT,n=206 | 1.71 ± 19.533 |
| Year1,Week24,PT,n=686 | -0.43 ± 8.267 |
| Year1,Week36,PT,n=193 | 0.13 ± 3.357 |
| Year1,Week48,PT,n=666 | -0.45 ± 8.174 |
| Year2,Week24,PT,n=626 | 0.15 ± 11.528 |
| Year2,Week48,PT,n=572 | -0.26 ± 8.925 |
| Year3,Week24,PT,n=521 | 0.12 ± 9.609 |
| Year3,Week48,PT,n=469 | 0.63 ± 14.334 |
| Year4,Week24,PT,n=422 | 0.06 ± 10.458 |
| Year4,Week48,PT,n=412 | 0.40 ± 4.228 |
| Year5,Week24,PT,n=384 | -0.14 ± 10.810 |
| Year5,Week48,PT,n=349 | 0.61 ± 11.276 |
| Year6,Week24,PT,n=292 | 0.64 ± 8.023 |
| Year6,Week48,PT,n=278 | 0.85 ± 12.414 |
| Year7,Week24,PT,n=177 | 1.76 ± 14.272 |
| Year7,Week48,PT,n=131 | 0.36 ± 2.290 |
| Year8,Week24,PT,n=52 | 1.21 ± 6.716 |
| Year8,Week48,PT,n=13 | 0.52 ± 0.600 |
| Year9,Week24,PT,n=6 | 0.50 ± 0.657 |
| Year9,Week48,PT,n=1 | 1.00 ± NA |
| Exit,PT, n=587 | 0.25 ± 9.973 |
| 8 Week, Follow up,n=524 | 0.50 ± 4.965 |
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Plt, Lymp, Leu, Eos, Baso, Mono, Neu, NeuBF, and NueS are summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| Billion cells per liter | Belimumab 10mg/kg IV |
|---|---|
| Baso,Year1,Week4,n=693 | 0.002 ± 0.0172 |
| Baso,Year1,Week12,n=694 | 0.002 ± 0.0187 |
| Baso,Year1,Week24,n=696 | 0.002 ± 0.0176 |
| Baso,Year1,Week36,n=682 | 0.002 ± 0.0179 |
| Baso,Year1,Week48,n=684 | 0.003 ± 0.0183 |
| Baso,Year2,Week24,n=629 | 0.004 ± 0.0190 |
| Baso,Year2,Week48,n=589 | 0.004 ± 0.0200 |
| Baso,Year3,Week24,n=533 | 0.005 ± 0.0165 |
| Baso,Year3,Week48,n=476 | 0.008 ± 0.0194 |
| Baso,Year4,Week24,n=446 | 0.007 ± 0.0192 |
| Baso,Year4,Week48,n=423 | 0.008 ± 0.0202 |
| Baso,Year5,Week24,n=389 | 0.007 ± 0.0191 |
| Baso,Year5,Week48,n=360 | 0.005 ± 0.0191 |
| Baso,Year6,Week24,n=306 | 0.006 ± 0.0184 |
| Baso,Year6,Week48,n=282 | 0.007 ± 0.0198 |
| Baso,Year7,Week24,n=181 | 0.007 ± 0.0211 |
| Baso,Year7,Week48,n=130 | 0.012 ± 0.0259 |
| Baso,Year8,Week24,n=52 | 0.014 ± 0.0187 |
| Baso,Year8,Week48,n=13 | 0.001 ± 0.0166 |
| Baso,Year9,Week24,n=6 | 0.003 ± 0.0082 |
| Baso,Year9,Week48,n=1 | 0.010 ± NA |
| Baso,Exit,n=614 | 0.005 ± 0.0204 |
| Baso,8 Week,Follow up,n=532 | 0.009 ± 0.0253 |
| Eos,Year1,Week4,n=693 | 0.007 ± 0.1597 |
| Eos,Year1,Week12,n=694 | 0.003 ± 0.1595 |
| Eos,Year1,Week24,n=696 | 0.000 ± 0.1614 |
| Eos,Year1,Week36,n=682 | 0.020 ± 0.1866 |
| Eos,Year1,Week48,n=684 | 0.001 ± 0.1763 |
| Eos,Year2,Week24,n=629 | 0.004 ± 0.1605 |
| Eos,Year2,Week48,n=589 | -0.004 ± 0.1858 |
| Eos,Year3,Week24,n=533 | -0.011 ± 0.2074 |
| Eos,Year3,Week48,n=476 | -0.026 ± 0.2053 |
| Eos,Year4,Week24,n=446 | -0.041 ± 0.1792 |
| Eos,Year4,Week48,n=423 | -0.047 ± 0.1676 |
| Eos,Year5,Week24,n=389 | -0.035 ± 0.1949 |
| Eos,Year5,Week48,n=360 | -0.045 ± 0.1807 |
| Eos,Year6,Week24,n=306 | -0.046 ± 0.1801 |
| Eos,Year6,Week48,n=282 | -0.037 ± 0.1976 |
| Eos,Year7,Week24,n=181 | -0.046 ± 0.1710 |
| Eos,Year7,Week48,n=130 | -0.020 ± 0.2276 |
| Eos,Year8,Week24,n=52 | -0.017 ± 0.1753 |
| Eos,Year8,Week48,n=13 | -0.041 ± 0.1130 |
| Eos,Year9,Week24,n=6 | -0.088 ± 0.1078 |
| Eos,Year9,Week48,n=1 | -0.040 ± NA |
| Eos, Exit, n=614 | -0.026 ± 0.1754 |
| Eso, 8 Week Follow up, n=532 | -0.030 ± 0.1920 |
| Leu,Year1,Week4,n=696 | 0.16 ± 1.928 |
| Leu,Year1,Week12,n=697 | 0.19 ± 2.106 |
| Leu,Year1,Week24,n=697 | 0.04 ± 2.142 |
| Leu,Year1,Week36,n=682 | 0.05 ± 2.190 |
| Leu,Year1,Week48,n=684 | 0.02 ± 2.274 |
| Leu,Year2,Week24,n=630 | -0.19 ± 2.287 |
| Leu,Year2,Week48,n=589 | -0.11 ± 2.449 |
| Leu,Year3,Week24,n=533 | -0.03 ± 2.544 |
| Leu,Year3,Week24,n=476 | 0.06 ± 2.393 |
| Leu,Year4,Week24,n=446 | -0.01 ± 2.520 |
| Leu,Year4,Week48,n=423 | -0.06 ± 2.661 |
| Leu,Year5,Week24,n=389 | 0.05 ± 2.430 |
| Leu,Year5,Week48,n=360 | -0.06 ± 2.463 |
| Leu,Year6,Week24,n=306 | 0.04 ± 2.449 |
| Leu,Year6,Week48,n=282 | 0.17 ± 2.579 |
| Leu,Year7,Week24,n=181 | 0.12 ± 2.395 |
| Leu,Year7,Week48,n=130 | 0.48 ± 2.354 |
| Leu,Year8,Week24,n=52 | 0.38 ± 2.761 |
| Leu,Year8,Week48,n=13 | -0.65 ± 3.136 |
| Leu,Year9,Week24,n=6 | -0.35 ± 3.422 |
| Leu,Year9,Week48,n=1 | -3.90 ± NA |
| Leu, Exit, n=614 | 0.18 ± 2.650 |
| Leu, 8 Week Follow up,n=532 | 0.21 ± 2.496 |
| Lymp,Year1,Week4,n=693 | 0.093 ± 0.5986 |
| Lymp,Year1,Week12,n=694 | 0.107 ± 0.6607 |
| Lymp,Year1,Week24,n=696 | 0.066 ± 0.6544 |
| Lymp,Year1,Week36,n=682 | 0.119 ± 0.6583 |
| Lymp,Year1,Week48,n=684 | 0.048 ± 0.6361 |
| Lymp,Year2,Week24,n=629 | 0.051 ± 0.6898 |
| Lymp,Year2,Week48,n=589 | 0.067 ± 0.6971 |
| Lymp,Year3,Week24,n=533 | 0.057 ± 0.6717 |
| Lymp,Year3,Week48,n=476 | 0.038 ± 0.6676 |
| Lymp,Year4,Week24,n=446 | 0.054 ± 0.6858 |
| Lymp,Year4,Week48,n=423 | 0.067 ± 0.7186 |
| Lymp,Year5,Week24,n=389 | 0.023 ± 0.6810 |
| Lymp,Year5,Week48,n=360 | 0.078 ± 0.7485 |
| Lymp,Year6,Week24,n=306 | 0.147 ± 0.7251 |
| Lymp,Year6,Week48,n=282 | 0.168 ± 0.7523 |
| Lymp,Year7,Week24,n=181 | 0.175 ± 0.7670 |
| Lymp,Year7,Week48,n=130 | 0.169 ± 0.6639 |
| Lymp,Year8,Week24,n=52 | 0.300 ± 0.7553 |
| Lymp,Year8,Week48,n=13 | 0.052 ± 0.5252 |
| Lymp,Year9,Week24,n=6 | -0.032 ± 0.6156 |
| Lymp,Year9,Week48,n=1 | -0.460 ± NA |
| Lymp,Exit,n=614 | 0.128 ± 0.7808 |
| Lymp,8 Week Follow up,n=532 | 0.140 ± 0.7453 |
| Mono,Year1,Week4,n=693 | 0.025 ± 0.2108 |
| Mono,Year1,Week12,n=694 | 0.036 ± 0.2043 |
| Mono,Year1,Week24,n=696 | 0.028 ± 0.2127 |
| Mono,Year1,Week36,n=682 | 0.053 ± 0.2053 |
| Mono,Year1,Week48,n=684 | 0.050 ± 0.2069 |
| Mono,Year2,Week24,n=629 | 0.034 ± 0.1992 |
| Mono,Year2,Week48,n=589 | 0.050 ± 0.2172 |
| Mono,Year3,Week24,n=533 | 0.053 ± 0.2314 |
| Mono,Year3,Week48,n=476 | 0.084 ± 0.1994 |
| Mono,Year4,Week24,n=446 | 0.071 ± 0.2085 |
| Mono,Year4,Week48,n=423 | 0.076 ± 0.2040 |
| Mono,Year5,Week24,n=389 | 0.089 ± 0.2015 |
| Mono,Year5,Week48,n=360 | 0.088 ± 0.2044 |
| Mono,Year6,Week24,n=306 | 0.087 ± 0.2043 |
| Mono,Year6,Week48,n=282 | 0.086 ± 0.2063 |
| Mono,Year7,Week24,n=181 | 0.113 ± 0.2155 |
| Mono,Year7,Week48,n=130 | 0.134 ± 0.2090 |
| Mono,Year8,Week24,n=52 | 0.173 ± 0.2014 |
| Mono,Year8,Week48,n=13 | 0.021 ± 0.1503 |
| Mono,Year9,Week24,n=6 | 0.022 ± 0.1931 |
| Mono,Year9,Week48,n=1 | -0.120 ± NA |
| Mono, Exit,n=614 | 0.083 ± 0.2157 |
| Mono, 8 Week Follow up, n=532 | 0.084 ± 0.2189 |
| Neu,Yaer1,Week4,n=688 | 0.024 ± 2.0482 |
| Neru,Year1,Week12,n=690 | 0.047 ± 2.1575 |
| Neu,Year1,Week24,n=691 | -0.059 ± 2.1845 |
| Neu,Year1,Week36,n=677 | -0.141 ± 2.1907 |
| Neu,Year1,Week48,n=679 | -0.078 ± 2.3164 |
| Neu,Year2,Week24,n=624 | -0.286 ± 2.2746 |
| Neu,Year2,Week48,n=584 | -0.230 ± 2.3963 |
| Neu,Year3,Week24,n=528 | -0.135 ± 2.4914 |
| Neu,Year3,Week48,n=471 | -0.049 ± 2.3683 |
| Neu,Year4,Week24,n=446 | -0.104 ± 2.3846 |
| Neu,Year4,Week48,n=423 | -0.160 ± 2.5563 |
| Neu,Year5,Week24,n=384 | -0.031 ± 2.3060 |
| Neu,Year5,Week48,n=356 | -0.198 ± 2.3952 |
| Neu,Year6,Week24,n=306 | -0.151 ± 2.3083 |
| Neu,Year6,Week48,n=282 | -0.060 ± 2.4314 |
| Neu,Year7,Week24,n=181 | -0.129 ± 2.3908 |
| Neu,Year7,Week48,n=130 | -0.687 ± 3.0412 |
| Neu,Year8,Week24,n=52 | -0.092 ± 2.3908 |
| Neu,Year8,Week48,n=13 | -0.687 ± 3.0412 |
| Neu,Year9,Week24,n=6 | -0.257 ± 2.9192 |
| Neu,Year9,Week48,n=1 | -3.300 ± NA |
| Neu, Exit, n=609 | -0.006 ± 2.5612 |
| Neu,8 Week Follow up,n=528 | 0.001 ± 2.3935 |
| NeuBF,Year1,Week4,n=4 | 0.013 ± 0.1473 |
| NeuBF,Year1,Week12,n=4 | 0.073 ± 0.1106 |
| NeuBF,Year1,Week24,n=5 | -0.000 ± 0.2699 |
| NeuBF,Year1,Week36,n=4 | 0.045 ± 0.0465 |
| NeuBF,Year1,Week48,n=2 | 0.105 ± 0.1909 |
| NeuBF,Year2,Week24,n=1 | 0.120 ± NA |
| NeuBF,Year3,Week24,n=1 | 0.070 ± NA |
| NeuBF,Exit,n=2 | 0.465 ± 0.6435 |
| NeuS,Year1,Week4,n=693 | 0.021 ± 2.0450 |
| NeuS,Year1,Week12,n=694 | 0.051 ± 2.1519 |
| NeuS,Year1,Week24,n=696 | -0.055 ± 2.1757 |
| NeuS,Year1,Week36,n=682 | -0.139 ± 2.1819 |
| NeuS,Year1,Week48,n=684 | -0.079 ± 2.3128 |
| NeuS,Year2,Week24,n=629 | -0.289 ± 2.2609 |
| NeuS,Year2,Week48,n=589 | -0.226 ± 2.3846 |
| NeuS,Year3,Week24,n=533 | -0.130 ± 2.4736 |
| NeuS,Year3,Week48,n=476 | -0.041 ± 2.3547 |
| NeuS,Year4,Week24,n=446 | -0.097 ± 2.3804 |
| NeuS,Year4,Week48,n=423 | -0.158 ± 2.5542 |
| NeuS,Year5,Week24,n=389 | -0.024 ± 2.2893 |
| NeuS,Year5,Week48,n=360 | -0.184 ± 2.3831 |
| NeuS,Year6,Week24,n=306 | -0.147 ± 2.3029 |
| NeuS,Year6,Week48,n=282 | -0.058 ± 2.4310 |
| NeuS,Year7,Week24,n=181 | -0.151 ± 2.2248 |
| NeuS,Year7,Week48,n=130 | 0.191 ± 2.2514 |
| NeuS,Year8,Week24,n=52 | -0.092 ± 2.3908 |
| NeuS,Year8,Week48,n=13 | -0.687 ± 3.0412 |
| NeuS,Year9,Week24,n=6 | -0.257 ± 2.9192 |
| NeuS,Year9,Week48,n=1 | -3.300 ± NA |
| NeuS,Exit,n=614 | -0.008 ± 2.5501 |
| NeuS,8 Week Followup,n=532 | 0.007 ± 2.3824 |
| Plt,Year1,Week4,n=683 | 8.1 ± 38.82 |
| Plt,Year1,Week12,n=690 | 4.6 ± 43.63 |
| Plt,Year1,Week24,n=687 | -0.5 ± 47.73 |
| Plt,Year1,Week36,n=680 | -2.9 ± 50.25 |
| Plt,Year1,Week48,n=677 | -9.3 ± 50.81 |
| Plt,Year2,Week24,n=631 | -15.4 ± 53.80 |
| Plt,Year2,Week48,n=583 | -20.3 ± 56.39 |
| Plt,Year3,Week24,n=526 | -19.9 ± 57.88 |
| Plt,Year3,Week48,n=476 | -13.4 ± 65.16 |
| Plt,Year4,Week24,n=441 | -14.0 ± 59.05 |
| Plt,Year4,Week48,n=420 | -18.2 ± 63.80 |
| Plt,Year5,Week24,n=388 | -19.3 ± 61.49 |
| Plt,Year5,Week48,n=360 | -17.9 ± 63.36 |
| Plt,Year6,Week24,n=305 | -13.3 ± 61.54 |
| Plt,Year6,Week48,n=282 | -13.4 ± 60.89 |
| Plt,Year7,Week24,n=181 | -15.3 ± 63.95 |
| Plt,Year7,Week48,n=130 | -16.3 ± 70.75 |
| Plt,Year8,Week24,n=52 | -2.3 ± 80.69 |
| Plt,Year8,Week48,n=13 | -29.9 ± 88.66 |
| Plt,Year9,Week24,n=6 | -5.0 ± 82.67 |
| Plt,Year9,Week48,n=1 | 57.0 ± NA |
| Plt,Exit,n=613 | -11.0 ± 64.36 |
| Plt,8Week Followup,n=530 | -11.2 ± 60.57 |
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Hg is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| Gram per liter (g/L) | Belimumab 10mg/kg IV |
|---|---|
| Hg,Year1, Week 4,n=697 | -0.3 ± 7.05 |
| Hg,Year1,Week12,n=698 | 0.1 ± 8.75 |
| Hg,Year1,Week24,n=699 | 0.1 ± 9.48 |
| Hg,Year1,Week36,n=688 | 0.3 ± 9.90 |
| Hg,Year1,Week48,n=686 | 1.0 ± 11.03 |
| Hg,Year2,Week24,n=635 | 1.0 ± 11.31 |
| Hg,Year2,Week48,n=591 | 1.3 ± 12.12 |
| Hg,Year3,Week24,n=534 | 2.2 ± 12.79 |
| Hg,Year3,Week48,n=478 | 2.9 ± 12.67 |
| Hg,Year4,Week24,n=446 | 2.6 ± 12.93 |
| Hg,Year,Week48,n=424 | 2.4 ± 13.59 |
| Hg,Year5,Week24,n=390 | 2.9 ± 12.76 |
| Hg,Year5,Week48,n=362 | 3.2 ± 13.26 |
| Hg,Year6,Week24,n=306 | 2.7 ± 13.19 |
| Hg,Year6,Week48,n=282 | 2.3 ± 13.83 |
| Hg,Year7,Week24,n=181 | 2.9 ± 14.54 |
| Hg,Year7,Week48,n=130 | 4.0 ± 14.66 |
| Hg,Year8,Week24,n=52 | 1.5 ± 14.84 |
| Hg,Year8,Week48,n=13 | -0.2 ± 13.95 |
| Hg,Year9,Week24,n=6 | -0.7 ± 20.67 |
| Hg,Year9,Week48,n=1 | -29.0 ± NA |
| Hg,Exit,n=619 | 3.2 ± 13.90 |
| Hg,8 Week Follow up,n=534 | 2.8 ± 13.71 |
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks). Change from Baseline in Hematocrit is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| Percentage of blood by volume | Belimumab 10mg/kg IV |
|---|---|
| Hematocrit,Year1,Week4,n=697 | 0.01 ± 2.250 |
| Hematocrit,Year1,Week12,n=698 | 0.38 ± 2.729 |
| Hematocrit,Year1,Week24,n=699 | 0.75 ± 2.928 |
| Hematocrit,Year1,Week36,n=688 | 0.53 ± 2.954 |
| Hematocrit,Year1,Week48,n=686 | 0.35 ± 3.286 |
| Hematocrit,Year2,Week24,n=635 | 0.94 ± 3.427 |
| Hematocrit,Year2,Week48,n=591 | 0.78 ± 3.584 |
| Hematocrit,Year3,Week24,n=534 | 1.29 ± 3.828 |
| Hematocrit,Year3,Week48,n=478 | 1.39 ± 3.800 |
| Hematocrit,Year4,Week24,n=446 | 1.67 ± 3.834 |
| Hematocrit,Year4,Week48,n=424 | 1.15 ± 3.998 |
| Hematocrit,Year5,Week24,n=390 | 1.69 ± 3.776 |
| Hematocrit,Year5,Week48,n=362 | 1.98 ± 3.842 |
| Hematocrit,Year6,Week24,n=306 | 1.93 ± 3.939 |
| Hematocrit,Year6,Week48,n=282 | 2.07 ± 4.023 |
| Hematocrit,Year7,Week24,n=181 | 1.81 ± 4.251 |
| Hematocrit,Year7,Week48,n=130 | 2.11 ± 4.238 |
| Hematocrit,Year8,Week24,n=52 | 1.42 ± 4.390 |
| Hematocrit,Year8,Week48,n=13 | 1.48 ± 4.234 |
| Hematocrit,Year9,Week24,n=6 | 2.03 ± 6.001 |
| Hematocrit,Year9,Week48,n=1 | -6.00 ± NA |
| Hematocrit,Exit,n=619 | 1.91 ± 4.202 |
| Hematocrit,8 Week Follow up,n=534 | 1.85 ± 4.077 |
Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Erythrocytes is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| Trillions cells per liter | Belimumab 10mg/kg IV |
|---|---|
| Eryth,Year1,Week4,n=697 | -0.00 ± 0.231 |
| Eryth,Year1,Week12,n=698 | 0.04 ± 0.280 |
| Eryth,Year1,Week24,n=699 | 0.06 ± 0.293 |
| Eryth,Year1,Week36,n=688 | 0.06 ± 0.299 |
| Eryth,Year1,Week48,n=686 | 0.06 ± 0.328 |
| Eryth,Year2,Week24,n=635 | 0.07 ± 0.335 |
| Eryth,Year2,Week48,n=591 | 0.04 ± 0.362 |
| Eryth,Year3,Week24,n=534 | 0.04 ± 0.364 |
| Eryth,Year3,Week48,n=478 | 0.05 ± 0.381 |
| Eryth,Year4,Week24,n=446 | 0.06 ± 0.372 |
| Eryth,Year,Week48,n=424 | 0.05 ± 0.379 |
| Eryth,Year5,Week24,n=390 | 0.09 ± 0.375 |
| Eryth,Year5,Week48,n=362 | 0.11 ± 0.383 |
| Eryth,Year6,Week24,n=306 | 0.12 ± 0.396 |
| Eryth,Year6,Week48,n=282 | 0.17 ± 0.408 |
| Eryth,Year7,Week24,n=181 | 0.17 ± 0.415 |
| Eryth,Year7,Week48,n=130 | 0.22 ± 0.387 |
| Eryth,Year8,Week24,n=52 | 0.21 ± 0.375 |
| Eryth,Year8,Week48,n=13 | 0.15 ± 0.207 |
| Eryth,Year9,Week24,n=6 | 0.30 ± 0.374 |
| Eryth,Year9,Week48,n=1 | 0.20 ± NA |
| Eryth,Exit,n=619 | 0.14 ± 0.431 |
| Eryth,8 Week Follow up,n=534 | 0.13 ± 0.411 |
Electrolytes parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 electrolytes parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ca,CO2, Chloride, Mg, Phos, K and Na were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| Millimoles per liter (mmol/L) | Belimumab 10mg/kg IV |
|---|---|
| Ca,Year1,Week4,n=697 | 0.0030 ± 0.0763 |
| Ca,Year1,Week12,n=696 | 0.0020 ± 0.0749 |
| Ca,Year1,Week24,n=696 | -0.0035 ± 0.0750 |
| Ca,Year1,Week36,n=677 | 0.0024 ± 0.0836 |
| Ca,Year1,Week48,n=687 | -0.0065 ± 0.0778 |
| Ca,Year2,Week24,n=636 | -0.0075 ± 0.0764 |
| Ca,Year2,Week48,n=587 | -0.0091 ± 0.0837 |
| Ca,Year3,Week24,n=526 | -0.0047 ± 0.0810 |
| Ca,Year3,Week48,n=481 | -0.0123 ± 0.0800 |
| Ca,Year4,Week24,n=438 | -0.0056 ± 0.0771 |
| Ca,Year,Week48,n=418 | -0.0193 ± 0.0805 |
| Ca,Year5,Week24,n=387 | -0.0129 ± 0.0885 |
| Ca,Year5,Week48,n=358 | -0.0140 ± 0.0919 |
| Ca,Year6,Week24,n=303 | -0.0053 ± 0.0903 |
| Ca,Year6,Week48,n=283 | -0.0146 ± 0.0870 |
| Ca,Year7,Week24,n=182 | -0.0076 ± 0.0839 |
| Ca,Year7,Week48,n=130 | -0.0079 ± 0.1172 |
| Ca,Year8,Week24,n=51 | 0.0003 ± 0.0806 |
| Ca,Year8,Week48,n=13 | -0.0395 ± 0.0611 |
| Ca,Year9,Week24,n=6 | -0.0402 ± 0.0336 |
| Ca,Year9,Week48,n=1 | -0.0642 ± NA |
| Ca,Exit,n=619 | 0.0006 ± 0.0864 |
| Ca,8 Week Follow up,n=534 | -0.0014 ± 0.0909 |
| CO2,Year1,Week4,n=701 | -0.0 ± 2.77 |
| CO2,Year1,Week12,n=700 | -0.1 ± 2.76 |
| CO2,Year1,Week24,n=701 | -0.1 ± 2.73 |
| CO2,Year1,Week36,n=682 | 0.1 ± 2.73 |
| CO2,Year1,Week48,n=692 | -0.1 ± 2.78 |
| CO2,Year2,Week24,n=641 | -0.3 ± 2.94 |
| CO2,Year2,Week48,n=692 | -0.3 ± 2.87 |
| CO2,Year3,Week24,n=531 | -0.2 ± 2.90 |
| CO2,Year3,Week48,n=486 | -0.4 ± 2.75 |
| CO2,Year4,Week24,n=438 | -0.0 ± 2.76 |
| CO2,Year4,Week48,n=418 | -0.5 ± 3.04 |
| CO2,Year5,Week24,n=393 | -0.2 ± 2.90 |
| CO2,Year5,Week48,n=361 | -0.8 ± 2.82 |
| CO2,Year6,Week24,n=303 | -0.0 ± 2.86 |
| CO2,Year6,Week48,n=284 | -0.5 ± 2.76 |
| CO2,Year7,Week24,n=182 | 0.2 ± 2.78 |
| CO2,Year7,Week48,n=130 | 0.2 ± 2.67 |
| CO2,Year8,Week24,n=52 | 1.0 ± 2.78 |
| CO2,Year8,Week48,n=13 | 0.4 ± 3.38 |
| CO2,Year9,Week24,n=6 | -0.3 ± 0.82 |
| CO2,Year9,Week48,n=1 | -3.0 ± NA |
| CO2,Exit,n=625 | -0.3 ± 3.00 |
| CO2,8 week Follow up,n=538 | -0.2 ± 3.00 |
| Chloride,Year1,Week4,n=707 | 0.3 ± 2.33 |
| Chloride,Year1,Week12,n=704 | 0.6 ± 2.56 |
| Chloride,Year1,Week24,n=703 | 0.6 ± 2.42 |
| Chloride,Year1,Week36,n=684 | 0.6 ± 2.47 |
| Chloride,Year1,Week48,n=693 | 0.4 ± 2.44 |
| Chloride,Year2,Week24,n=643 | 0.5 ± 2.62 |
| Chloride,Year2,Week48,n=598 | 0.5 ± 2.81 |
| Chloride,Year3,Week24,n=535 | 0.7 ± 3.04 |
| Chloride,Year3,Week48,n=488 | 0.6 ± 2.73 |
| Chloride,Year4,Week24,n=439 | 0.5 ± 2.74 |
| Chloride,Year4,Week48,n=421 | 0.7 ± 2.84 |
| Chloride,Year5,Week24,n=392 | 0.6 ± 2.95 |
| Chloride,Year5,Week48,n=362 | 0.6 ± 2.77 |
| Chloride,Year6,Week24,n=304 | 1.0 ± 2.74 |
| Chloride,Year6,Week48,n=286 | 0.8 ± 2.67 |
| Chloride,Year7,Week24,n=183 | 0.7 ± 2.57 |
| Chloride,Year7,Week48,n=130 | 1.1 ± 2.73 |
| Chloride,Year8,Week24,n=52 | 1.3 ± 2.86 |
| Chloride,Year8,Week48,n=13 | 1.2 ± 3.54 |
| Chloride,Year9,Week24,n=6 | 3.2 ± 1.47 |
| Chloride,Year9,Week48,n=1 | 1.0 ± NA |
| Chloride,Exit,n=624 | 0.4 ± 3.06 |
| Chloride,8 Week Follow up,n=538 | 0.4 ± 2.82 |
| Mg,Year1,Week4,n=707 | -0.003 ± 0.0583 |
| Mg,Year1,Week 12,n=705 | -0.006 ± 0.0647 |
| Mg,Year1,Week 24,n=703 | -0.003 ± 0.0604 |
| Mg,Year1,Week 36,n=684 | -0.004 ± 0.0616 |
| Mg,Year1,Week 48,n=693 | 0.002 ± 0.0597 |
| Mg,Year2,Week 24,n=643 | 0.002 ± 0.0694 |
| Mg,Year2,Week 48,n=598 | 0.001 ± 0.0711 |
| Mg,Year3,Week 24,n=535 | 0.010 ± 0.0668 |
| Mg,Year3,Week 48,n=488 | 0.010 ± 0.0669 |
| Mg,Year4,Week 24,n=439 | 0.016 ± 0.0700 |
| Mg,Year4,Week 48,n=421 | 0.017 ± 0.0709 |
| Mg,Year 5,Week 24,n=393 | 0.016 ± 0.0673 |
| Mg,Year 5,Week 48,n=362 | 0.021 ± 0.0688 |
| Mg,Year 6,Week 24,n=304 | 0.013 ± 0.0718 |
| Mg,Year 6,Week 48,n=286 | 0.011 ± 0.0639 |
| Mg,Year 7,Week 24,n=183 | 0.010 ± 0.0692 |
| Mg,Year 7,Week 48,n=130 | 0.013 ± 0.0635 |
| Mg,Year 8,Week 24,n=52 | 0.025 ± 0.0702 |
| Mg,Year 8,Week 48,n=13 | 0.042 ± 0.0685 |
| Mg,Year 9,Week 24,n=6 | 0.030 ± 0.0613 |
| Mg,Year 9,Week 48,n=1 | 0.040 ± NA |
| Mg, Exit,n=625 | 0.022 ± 0.0738 |
| Mg,8 Week Follow up,n=539 | 0.021 ± 0.0729 |
| Phos, Year1, Week4,n=707 | 0.0102 ± 0.1908 |
| Phos, Year1, Week12,n=705 | 0.0004 ± 0.1999 |
| Phos, Year1, Week24,n=703 | -0.0126 ± 0.1964 |
| Phos, Year1, Week 36,n=684 | 0.0101 ± 0.1976 |
| Phos, Year1, Week48,n=693 | -0.0110 ± 0.2086 |
| Phos, Year2, Week24,n=643 | -0.0026 ± 0.2138 |
| Phos, Year2, Week48,n=598 | -0.0044 ± 0.2062 |
| Phos, Year3, Week24,n=535 | -0.0109 ± 0.2028 |
| Phos, Year3, Week48,n=488 | -0.0185 ± 0.2138 |
| Phos, Year4, Week24,n=439 | -0.0072 ± 0.2067 |
| Phos, Year4, Week48,n=421 | -0.0143 ± 0.2118 |
| Phos, Year5, Week24,n=393 | -0.0199 ± 0.2751 |
| Phos, Year5, Week48,n=362 | -0.0320 ± 0.2145 |
| Phos, Year6, Week24,n=304 | -0.0238 ± 0.2214 |
| Phos, Year6, Week48,n=286 | -0.0123 ± 0.2113 |
| Phos, Year 7, Week 24,n=183 | -0.0196 ± 0.1970 |
| Phos, Year 7, Week 48,n=130 | -0.0101 ± 0.1912 |
| Phos, Year 8, Week 24,n=52 | -0.0041 ± 0.2038 |
| Phos, Year 8, Week48,n=13 | -0.0340 ± 0.1337 |
| Phos, Year9, Week 24,n=6 | -0.0803 ± 0.0823 |
| Phos, Year 9, Week 48,n=1 | 0.0447 ± NA |
| Phos, Exit, n=625 | -0.0111 ± 0.2243 |
| Phos, 8 Week Follow up,n=539 | -0.0034 ± 0.2233 |
| K, Year 1, Week 4, n=701 | 0.07 ± 0.411 |
| K, Year 1, Week 12, n=700 | 0.03 ± 0.380 |
| K, Year 1, Week 24, n=701 | 0.01 ± 0.377 |
| K, Year 1, Week 36, n=682 | 0.04 ± 0.387 |
| K, Year 1, Week 48, n=692 | 0.01 ± 0.377 |
| K, Year 2, Week 24, n=641 | 0.01 ± 0.393 |
| K, Year 2, Week 48, n=592 | 0.02 ± 0.372 |
| K, Year 3, Week 24, n=531 | 0.05 ± 0.401 |
| K, Year 3, Week 48, n=486 | 0.06 ± 0.421 |
| K, Year 4, Week 24, n=438 | 0.06 ± 0.408 |
| K, Year 4, Week 48, n=418 | 0.03 ± 0.397 |
| K, Year 5, Week 24, n=393 | 0.08 ± 0.427 |
| K, Year 5, Week 48, n=362 | 0.02 ± 0.404 |
| K, Year 6, Week 24, n=303 | 0.06 ± 0.429 |
| K, Year 6, Week 48, n=284 | 0.05 ± 0.437 |
| K, Year 7, Week 24, n=182 | 0.05 ± 0.445 |
| K, Year 7, Week 48, n=130 | 0.05 ± 0.413 |
| K, Year 8, Week 24, n=52 | -0.02 ± 0.418 |
| K, Year 8, Week 48, n=13 | -0.12 ± 0.300 |
| K, Year 9, Week 24, n=6 | 0.05 ± 0.259 |
| K, Year 9, Week 48, n=1 | 0.00 ± NA |
| K, Exit, n=624 | 0.06 ± 0.435 |
| K, 8 Week Follow up, n=537 | 0.07 ± 0.452 |
| Na, Year 1, Week 4, n=707 | 0.1 ± 2.07 |
| Na, Year 1, Week 12, n=705 | 0.3 ± 2.25 |
| Na, Year 1, Week 24, n=703 | 0.4 ± 2.16 |
| Na, Year 1, Week 36, n=684 | 0.4 ± 2.10 |
| Na, Year 1, Week 48, n=693 | 0.1 ± 2.09 |
| Na, Year 2, Week 24, n=643 | -0.0 ± 2.30 |
| Na, Year 2, Week 48, n=598 | 0.1 ± 2.63 |
| Na, Year 3, Week 24, n=535 | 0.2 ± 2.54 |
| Na, Year 3, Week 48, n=488 | 0.3 ± 2.36 |
| Na, Year 4, Week 24, n=439 | 0.1 ± 2.31 |
| Na, Year 4, Week 48, n=421 | 0.3 ± 2.36 |
| Na, Year 5, Week 24, n=393 | 0.3 ± 2.61 |
| Na, Year 5, Week 48, n=362 | 0.3 ± 2.18 |
| Na, Year 6, Week 24, n=304 | 0.3 ± 2.22 |
| Na, Year 6, Week 48, n=286 | 0.4 ± 2.44 |
| Na, Year 7, Week 24, n=183 | 0.1 ± 2.22 |
| Na, Year 7, Week 48, n=130 | 0.1 ± 2.38 |
| Na, Year 8, Week 24, n=52 | 0.2 ± 2.67 |
| Na, Year 8, Week 48, n=13 | 0.1 ± 2.14 |
| Na, Year 9, Week 24, n=6 | 1.0 ± 1.79 |
| Na, Year 9, Week 48, n=1 | -3.0 ± NA |
| Na, Exist, n=624 | 0.1 ± 2.55 |
| Na, 8 Week Follow up, n=538 | 0.3 ± 2.36 |
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN/Cr is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Ratio | Belimumab 10mg/kg IV |
|---|---|
| BUN/Cr,Year1,Week4,n=707 | -0.2 ± 4.66 |
| BUN/Cr,Year1,Week12,n=705 | -0.3 ± 4.88 |
| BUN/CrYear1,Week24,n=703 | -0.7 ± 5.02 |
| BUN/Cr,Year1,Week36,n=683 | -0.5 ± 5.61 |
| BUN/Cr,Year1,Week48,n=693 | -0.2 ± 5.26 |
| BUN/Cr,Year2,Week24,n=643 | -0.1 ± 5.68 |
| BUN/Cr,Year2,Week48,n=598 | 0.5 ± 5.55 |
| BUN/Cr,Year3,Week24,n=535 | 1.4 ± 5.48 |
| BUN/Cr,Year3,Week48,n=488 | 1.2 ± 5.92 |
| BUN/Cr,Year4,Week24,n=439 | 1.4 ± 5.65 |
| BUN/Cr,Year 4,Week48,n=421 | 1.0 ± 5.85 |
| BUN/Cr,Year5,Week24,n=393 | 0.7 ± 5.51 |
| BUN/Cr,Year5,Week48,n=362 | 1.0 ± 5.62 |
| BUN/Cr,Year6,Week24,n=304 | 1.0 ± 5.35 |
| BUN/Cr,Year6,Week48,n=286 | 1.3 ± 5.74 |
| BUN/Cr,Year7,Week24,n=183 | 0.8 ± 5.68 |
| BUN/Cr,Year7,Week48,n=130 | 1.2 ± 5.47 |
| BUN/Cr,Year8,Week24,n=52 | 3.3 ± 4.64 |
| BUN/Cr,Year8,Week48,n=13 | 3.5 ± 6.04 |
| BUN/Cr,Year9,Week24,n=6 | 3.5 ± 3.08 |
| BUN/Cr,Year9,Week48,n=1 | 1 ± 2.0 |
| BUN/Cr,Exit,n=625 | 0.9 ± 6.05 |
| BUN/Cr,8 Week Follow up,n=539 | 0.9 ± 5.91 |
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Alb and Protein were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| Grams per liter (g/L) | Belimumab 10mg/kg IV |
|---|---|
| Alb,Year1,Week4,n=707 | -0.1 ± 2.36 |
| Alb,Year1,Week12,n=705 | 0.2 ± 2.67 |
| Alb,Year1,Week24,n=703 | 0.6 ± 3.03 |
| Alb,Year1,Week36,n=684 | 0.7 ± 3.23 |
| Alb,Year1,Week48,n=693 | 1.2 ± 3.52 |
| Alb,Year2,Week24,n=643 | 1.2 ± 3.49 |
| Alb,Year2,Week48,n=598 | 1.2 ± 3.67 |
| Alb,Year3,Week24,n=535 | 1.2 ± 3.78 |
| Alb,Year3,Week48,n=488 | 1.4 ± 4.02 |
| Alb,Year4,Week24,n=439 | 1.7 ± 4.02 |
| Alb,Year 4,Week48,n=421 | 1.9 ± 4.04 |
| Alb,Year5,Week24,n=393 | 1.9 ± 3.85 |
| Alb,Year5,Week48,n=362 | 2.3 ± 3.89 |
| Alb,Year6,Week24,n=304 | 2.2 ± 3.78 |
| Alb,Year6,Week48,n=286 | 2.1 ± 4.07 |
| Alb,Year7,Week24,n=183 | 2.0 ± 3.60 |
| Alb,Year7,Week48,n=130 | 2.3 ± 3.92 |
| Alb,Year8,Week24,n=52 | 1.9 ± 4.16 |
| Alb,Year8,Week48,n=13 | 1.1 ± 4.11 |
| Alb,Year9,Week24,n=6 | 0.7 ± 3.01 |
| Alb,Year9,Week48,n=1 | 1.0 ± NA |
| Alb,Exit,n=625 | 1.8 ± 4.74 |
| Alb,8 Week Follow up,n=539 | 1.7 ± 4.66 |
| Pro,Year1,Week4,n=707 | -1.4 ± 3.81 |
| Pro,Year1,Week12,n=705 | -2.0 ± 4.30 |
| Pro,Year1,Week24,n=703 | -1.9 ± 4.68 |
| Pro,Year1,Week36,n=684 | -2.3 ± 4.75 |
| Pro,Year1,Week48,n=693 | -1.8 ± 4.94 |
| Pro,Year2,Week24,n=643 | -2.3 ± 5.05 |
| Pro,Year2,Week48,n=598 | -2.7 ± 5.53 |
| Pro,Year3,Week24,n=535 | -3.1 ± 5.62 |
| Pro,Year3,Week48,n=488 | -3.5 ± 5.91 |
| Pro,Year4,Week24,n=439 | -3.2 ± 5.87 |
| Pro,Year 4,Week48,n=421 | -3.2 ± 6.07 |
| Pro,Year5,Week24,n=393 | -3.5 ± 5.75 |
| Pro,Year5,Week48,n=362 | -3.6 ± 5.78 |
| Pro,Year6,Week24,n=304 | -3.9 ± 5.57 |
| Pro,Year6,Week48,n=286 | -4.0 ± 5.79 |
| Pro,Year7,Week24,n=183 | -4.3 ± 5.36 |
| Pro,Year7,Week48,n=130 | -3.9 ± 5.32 |
| Pro,Year8,Week24,n=52 | -5.1 ± 6.38 |
| Pro,Year8,Week48,n=13 | -4.8 ± 5.02 |
| Pro,Year9,Week24,n=6 | -7.7 ± 7.03 |
| Pro,Year9,Week48,n=1 | 0.0 ± NA |
| Pro,Exit,n=625 | -3.4 ± 6.45 |
| Pro,8 Week Follow up,n=539 | -3.7 ± 6.42 |
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN and Glucose were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| mmol/L | Belimumab 10mg/kg IV |
|---|---|
| BUN,Year1,Week4,n=707 | 0.0299 ± 1.6783 |
| BUN,Year1,Week12,n=705 | 0.0402 ± 1.9768 |
| BUN,Year1,Week24,n=703 | -0.1443 ± 1.3723 |
| BUN,Year1,Week36,n=683 | -0.0592 ± 1.6916 |
| BUN,Year1,Week48,n=693 | -0.0406 ± 1.5541 |
| BUN,Year2,Week24,n=643 | -0.0760 ± 1.6652 |
| BUN,Year2,Week48,n=598 | 0.0631 ± 1.6429 |
| BUN,Year3,Week24,n=535 | 0.0524 ± 1.6850 |
| BUN,Year3,Week48,n=488 | -0.1013 ± 1.6910 |
| BUN,Year4,Week24,n=439 | 0.0967 ± 1.9398 |
| BUN,Year 4,Week48,n=421 | 0.0672 ± 2.1393 |
| BUN,Year5,Week24,n=393 | -0.0291 ± 2.0169 |
| BUN,Year5,Week48,n=362 | 0.0899 ± 2.0903 |
| BUN,Year6,Week24,n=304 | 0.0959 ± 1.9852 |
| BUN,Year6,Week48,n=286 | 0.2325 ± 2.2724 |
| BUN,Year7,Week24,n=183 | -0.0026 ± 1.6623 |
| BUN,Year7,Week48,n=130 | 0.1455 ± 1.7145 |
| BUN,Year8,Week24,n=52 | 0.5458 ± 1.7299 |
| BUN,Year8,Week48,n=13 | 0.3883 ± 1.4603 |
| BUN,Year9,Week24,n=6 | 0.1648 ± 1.0466 |
| BUN,Year9,Week48,n=1 | 0.5700 ± NA |
| BUN,Exit,n=625 | 0.2448 ± 2.4618 |
| BUN,8 Week Follow up,n=539 | 0.0822 ± 2.5567 |
| Glucose,Year1,Week4,n=707 | -0.0031 ± 1.0221 |
| Glucose,Year1,Week12,n=705 | 0.0333 ± 1.0627 |
| Glucose,Year1,Week24,n=702 | -0.0396 ± 1.2656 |
| Glucose,Year1,Week36,n=684 | 0.0099 ± 1.0269 |
| Glucose,Year1,Week48,n=693 | 0.0010 ± 1.1726 |
| Glucose,Year2,Week24,n=643 | 0.0143 ± 1.3227 |
| Glucose,Year2,Week48,n=598 | -0.0082 ± 1.1352 |
| Glucose,Year3,Week24,n=535 | -0.0159 ± 1.3222 |
| Glucose,Year3,Week48,n=488 | 0.0309 ± 1.1841 |
| Glucose,Year4,Week24,n=439 | -0.0160 ± 1.2213 |
| Glucose,Year 4,Week48,n=421 | -0.0259 ± 1.1936 |
| Glucose,Year5,Week24,n=393 | 0.0554 ± 1.1255 |
| Glucose,Year5,Week48,n=362 | 0.0655 ± 1.2946 |
| Glucose,Year6,Week24,n=303 | 0.1290 ± 1.1163 |
| Glucose,Year6,Week48,n=286 | 0.2001 ± 1.2411 |
| Glucose,Year7,Week24,n=183 | 0.2303 ± 1.0514 |
| Glucose,Year7,Week48,n=130 | 0.2335 ± 0.8346 |
| Glucose,Year8,Week24,n=52 | 0.3301 ± 0.9052 |
| Glucose,Year8,Week48,n=13 | 0.1431 ± 0.8115 |
| Glucose,Year9,Week24,n=6 | 0.2128 ± 0.4914 |
| Glucose,Year9,Week48,n=1 | 0.4739 ± NA |
| Glucose,Exit,n=624 | 0.1842 ± 1.8723 |
| Glucose,8 Week Follow up,n=539 | 0.0338 ± 1.4139 |
Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Cr and Urate were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| Micromoles per liter (µmol/L) | Belimumab 10mg/kg IV |
|---|---|
| Urate,Year1,Week4,n=707 | 1.0332 ± 45.8504 |
| Urate,Year1,Week12,n=704 | 0.4089 ± 54.3182 |
| Urate,Year1,Week24,n=703 | -0.0510 ± 49.2328 |
| Urate,Year1,Week36,n=684 | 0.6713 ± 50.7341 |
| Urate,Year1,Week48,n=693 | -1.5147 ± 50.5928 |
| Urate,Year2,Week24,n=643 | 2.7246 ± 55.7467 |
| Urate,Year2,Week48,n=598 | 4.1255 ± 60.0251 |
| Urate,Year3,Week24,n=535 | 6.7497 ± 60.4118 |
| Urate,Year3,Week48,n=488 | 6.9744 ± 63.6876 |
| Urate,Year4,Week24,n=439 | 5.9658 ± 66.6167 |
| Urate,Year 4,Week48,n=421 | 4.0772 ± 67.9587 |
| Urate,Year5,Week24,n=393 | -0.5634 ± 66.9130 |
| Urate,Year5,Week48,n=362 | -0.8979 ± 67.3843 |
| Urate,Year6,Week24,n=304 | 2.9530 ± 62.3168 |
| Urate,Year6,Week48,n=286 | 1.1244 ± 67.3175 |
| Urate,Year7,Week24,n=183 | 2.1521 ± 53.0854 |
| Urate,Year7,Week48,n=130 | 4.0062 ± 58.3577 |
| Urate,Year8,Week24,n=52 | -1.1003 ± 51.8840 |
| Urate,Year8,Week48,n=13 | 29.2043 ± 80.1811 |
| Urate,Year9,Week24,n=6 | 0.2187 ± 45.1947 |
| Urate,Year9,Week48,n=1 | -69.6640 ± NA |
| Urate,Exit,n=625 | 1.6479 ± 74.4078 |
| Urate,8 Week Follow up,n=539 | -2.7404 ± 75.5887 |
| Cr,Year1,Week4,n=707 | 0.913 ± 14.2222 |
| Cr,Year1,Week12,n=705 | 0.751 ± 14.0933 |
| Cr,Year1,Week24,n=703 | 0.823 ± 9.5372 |
| Cr,Year1,Week36,n=684 | 1.313 ± 13.1107 |
| Cr,Year1,Week48,n=693 | 0.439 ± 11.1364 |
| Cr,Year2,Week24,n=643 | -0.217 ± 13.9502 |
| Cr,Year2,Week48,n=598 | -0.922 ± 13.6541 |
| Cr,Year3,Week24,n=535 | -3.870 ± 17.8146 |
| Cr,Year3,Week48,n=488 | -4.844 ± 17.7059 |
| Crea,Year4,Week24,n=439 | -3.196 ± 22.2874 |
| Crea,Year 4,Week48,n=421 | -2.145 ± 30.9370 |
| Cr,Year5,Week24,n=393 | -1.999 ± 32.6689 |
| Cr,Year5,Week48,n=362 | -1.918 ± 28.8788 |
| Cr,Year6,Week24,n=304 | -2.125 ± 24.2374 |
| Cr,Year6,Week48,n=286 | -1.534 ± 28.8012 |
| Cr,Year7,Week24,n=183 | -2.511 ± 15.6881 |
| Cr,Year7,Week48,n=130 | -2.586 ± 14.0864 |
| Cr,Year8,Week24,n=52 | -4.659 ± 16.3056 |
| Cr,Year8,Week48,n=13 | -6.175 ± 6.6311 |
| Cr,Year9,Week24,n=6 | -8.933 ± 5.6925 |
| Cr,Year9,Week48,n=1 | 0.040 ± NA |
| Cr,Exit,n=624 | 0.606 ± 35.9813 |
| Cr,8 Week Follow up,n=539 | -1.108 ± 39.0635 |
Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in ALT, ALP, AST, GGT and LDH were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.NA indicates standard deviation was not calculable for a single data point.
| International Units/liter (IU/L) | Belimumab 10mg/kg IV |
|---|---|
| ALT, Year 1 Week 4, n=707 | -0.4 ± 10.18 |
| ALT, Year 1 Week 12, n=705 | -0.9 ± 12.31 |
| ALT, Year 1 Week 24, n=703 | -0.9 ± 19.46 |
| ALT, Year 1 Week 36, n=684 | -1.0 ± 15.61 |
| ALT, Year 1 Week 48, n=693 | -0.7 ± 15.04 |
| ALT, Year 2 Week 24, n=643 | 0.2 ± 23.56 |
| ALT, Year 2 Week 48, n=598 | 2.7 ± 57.67 |
| ALT, Year 3 Week 24, n=535 | -1.3 ± 14.40 |
| ALT, Year 3 Week 48, n=488 | 0.1 ± 21.21 |
| ALT, Year 4 Week 24, n=439 | -0.1 ± 18.72 |
| ALT, Year 4 Week 48, n=421 | -0.6 ± 17.59 |
| ALT, Year 5 Week 24, n=393 | -1.3 ± 18.74 |
| ALT, Year 5 Week 48, n=362 | -0.4 ± 22.72 |
| ALT, Year 6 Week 24, n=304 | -0.2 ± 20.54 |
| ALT, Year 6 Week 48, n=286 | 0.9 ± 20.94 |
| ALT, Year 7 Week 24, n=183 | 1.3 ± 19.46 |
| ALT, Year 7 Week 48, n=130 | -0.1 ± 16.79 |
| ALT, Year 8 Week 24, n=52 | 2.7 ± 31.15 |
| ALT, Year 8 Week 48, n=13 | 5.8 ± 33.54 |
| ALT, Year 9 Week 24, n=6 | 9.3 ± 27.77 |
| ALT, Year 9 Week 48, n=1 | -6.0 ± NA |
| ALT, Exit, n=624 | -0.6 ± 17.03 |
| ALT, 8 Week follow-up, n=539 | -0.8 ± 17.06 |
| ALP, Year 1 Week 4, n=707 | 0.0 ± 11.85 |
| ALP, Year 1 Week 12, n=705 | 0.5 ± 13.31 |
| ALP, Year 1 Week 24, n=703 | 2.1 ± 17.76 |
| ALP, Year 1 Week 36, n=684 | 1.7 ± 22.81 |
| ALP, Year 1 Week 48, n=693 | 4.6 ± 21.18 |
| ALP, Year 2 Week 24, n=643 | 5.1 ± 21.58 |
| ALP, Year 2 Week 48, n=598 | 6.1 ± 23.23 |
| ALP, Year 3 Week 24, n=535 | 5.9 ± 18.95 |
| ALP, Year 3 Week 48, n=488 | 7.3 ± 22.22 |
| ALP, Year 4 Week 24, n=439 | 7.2 ± 21.56 |
| ALP, Year 4 Week 48, n=421 | 8.1 ± 27.35 |
| ALP, Year 5 Week 24, n=393 | 7.2 ± 21.01 |
| ALP, Year 5 Week 48, n=362 | 8.5 ± 20.61 |
| ALP, Year 6 Week 24, n=304 | 9.4 ± 23.28 |
| ALP, Year 6 Week 48, n=286 | 11.5 ± 27.39 |
| ALP, Year 7 Week 24, n=183 | 10.9 ± 28.08 |
| ALP, Year 7 Week 48, n=130 | 7.5 ± 22.50 |
| ALP, Year 8 Week 24, n=52 | 12.9 ± 26.64 |
| ALP, Year 8 Week 48, n=13 | 6.1 ± 30.04 |
| ALP, Year 9 Week 24, n=6 | 4.2 ± 35.43 |
| ALP, Year 9 Week 48, n=1 | 12.0 ± NA |
| ALP, Exit, n=625 | 7.5 ± 25.35 |
| ALP, 8 Week follow-up, n=539 | 6.1 ± 23.00 |
| AST, Year 1 Week 4, n=701 | -0.6 ± 10.56 |
| AST, Year 1 Week 12, n=700 | -1.3 ± 14.12 |
| AST, Year 1 Week 24, n=701 | -1.0 ± 20.79 |
| AST, Year 1 Week 36, n=682 | -1.0 ± 17.88 |
| AST, Year 1 Week 48, n=692 | -0.9 ± 14.38 |
| AST, Year 2 Week 24, n=641 | -0.4 ± 22.22 |
| AST, Year 2 Week 48, n=592 | 2.9 ± 57.25 |
| AST, Year 3 Week 24, n=531 | -1.4 ± 13.26 |
| AST, Year 3 Week 48, n=486 | -0.5 ± 17.23 |
| AST, Year 4 Week 24, n=438 | -0.9 ± 14.60 |
| AST, Year 4 Week 48, n=418 | -0.7 ± 15.32 |
| AST, Year 5 Week 24, n=393 | -1.3 ± 16.07 |
| AST, Year 5 Week 48, n=362 | -0.8 ± 18.57 |
| AST, Year 6 Week 24, n=303 | -0.5 ± 16.95 |
| AST, Year 6 Week 48, n=284 | -0.2 ± 19.00 |
| AST, Year 7 Week 24, n=182 | 0.6 ± 13.43 |
| AST, Year 7 Week 48, n=130 | -0.3 ± 10.78 |
| AST, Year 8 Week 24, n=52 | 3.0 ± 33.93 |
| AST, Year 8 Week 48, n=13 | 5.8 ± 24.01 |
| AST, Year 9 Week 24, n=6 | 7.7 ± 19.63 |
| AST, Year 9 Week 48, n=1 | 0.0 ± NA |
| AST, Exit, n=625 | -0.6 ± 18.88 |
| AST, 8 Week follow-up, n=539 | -1.1 ± 16.58 |
| GGT, Year 1 Week 4, n=707 | -0.4 ± 23.39 |
| GGT, Year 1 Week 12, n=705 | -1.4 ± 23.12 |
| GGT, Year 1 Week 24, n=703 | -0.2 ± 39.50 |
| GGT, Year 1 Week 36, n=684 | 1.0 ± 64.60 |
| GGT, Year 1 Week 48, n=693 | 0.9 ± 35.99 |
| GGT, Year 2 Week 24, n=643 | -0.7 ± 34.81 |
| GGT, Year 2 Week 48, n=598 | 0.1 ± 34.63 |
| GGT, Year 3 Week 24, n=535 | -1.6 ± 33.88 |
| GGT, Year 3 Week 48, n=488 | 1.7 ± 45.42 |
| GGT, Year 4 Week 24, n=439 | 0.1 ± 39.13 |
| GGT, Year 4 Week 48, n=421 | 1.1 ± 54.41 |
| GGT, Year 5 Week 24, n=393 | -2.0 ± 37.17 |
| GGT, Year 5 Week 48, n=362 | -0.7 ± 43.39 |
| GGT, Year 6 Week 24, n=304 | -1.0 ± 42.04 |
| GGT, Year 6 Week 48, n=286 | 1.3 ± 41.84 |
| GGT, Year 7 Week 24, n=183 | 1.8 ± 37.06 |
| GGT, Year 7 Week 48, n=130 | -1.0 ± 27.86 |
| GGT, Year 8 Week 24, n=52 | 2.7 ± 39.90 |
| GGT, Year 8 Week 48, n=13 | -0.3 ± 27.97 |
| GGT, Year 9 Week 24, n=6 | 13.3 ± 26.96 |
| GGT, Year 9 Week 48, n=1 | -7.0 ± NA |
| GGT, Exit, n=625 | 0.7 ± 41.40 |
| GGT, 8 Week follow-up, n=539 | 0.2 ± 39.22 |
| LDH, Year 1 Week 4, n=701 | -4.1 ± 77.93 |
| LDH, Year 1 Week 12, n=700 | -6.0 ± 80.55 |
| LDH, Year 1 Week 24, n=701 | -6.6 ± 80.09 |
| LDH, Year 1 Week 36, n=682 | -8.8 ± 80.05 |
| LDH, Year 1 Week 48, n=692 | -7.3 ± 81.32 |
| LDH, Year 2 Week 24, n=641 | -9.4 ± 85.83 |
| LDH, Year 2 Week 48, n=592 | -9.6 ± 95.52 |
| LDH, Year 3 Week 24, n=532 | -11.8 ± 93.90 |
| LDH, Year 3 Week 48, n=486 | -15.1 ± 94.65 |
| LDH, Year 4 Week 24, n=438 | -16.5 ± 99.93 |
| LDH, Year 4 Week 48, n=418 | -16.9 ± 102.11 |
| LDH, Year 5 Week 24, n=393 | -17.5 ± 106.45 |
| LDH, Year 5 Week 48, n=362 | -19.8 ± 108.33 |
| LDH, Year 6 Week 24, n=303 | -21.7 ± 115.77 |
| LDH, Year 6 Week 48, n=284 | -21.3 ± 122.62 |
| LDH, Year 7 Week 24, n=182 | -15.2 ± 44.05 |
| LDH, Year 7 Week 48, n=130 | -16.3 ± 42.51 |
| LDH, Year 8 Week 24, n=52 | -14.3 ± 40.14 |
| LDH, Year 8 Week 48, n=13 | -31.5 ± 53.04 |
| LDH, Year 9 Week 24, n=6 | -27.2 ± 32.64 |
| LDH, Year 9 Week 48, n=1 | -65.0 ± NA |
| LDH, Exit, n=624 | -13.1 ± 90.39 |
| LDH, 8 Week follow-up, n=538 | -12.7 ± 95.65 |
Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Bili were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| µmol/L | Belimumab 10mg/kg IV |
|---|---|
| Year 1 Week 4, n=707 | 0.142 ± 2.8398 |
| Year 1 Week 12, n=705 | 0.008 ± 2.6383 |
| Year 1 Week 24, n=703 | 0.217 ± 3.1280 |
| Year 1 Week 36, n=684 | 0.173 ± 2.7566 |
| Year 1 Week 48, n=693 | 0.367 ± 2.8441 |
| Year 2 Week 24, n=643 | 0.488 ± 2.9346 |
| Year 2 Week 48, n=598 | 0.540 ± 3.2181 |
| Year 3 Week 24, n=535 | 0.606 ± 3.1612 |
| Year 3 Week 48, n=488 | 0.637 ± 3.2474 |
| Year 4 Week 24, n=439 | 0.548 ± 2.9773 |
| Year 4 Week 48, n=421 | 0.629 ± 3.4680 |
| Year 5 Week 24, n=393 | 0.410 ± 2.6931 |
| Year 5 Week 48, n=362 | 0.788 ± 3.1324 |
| Year 6 Week 24, n=304 | 0.801 ± 2.9946 |
| Year 6 Week 48, n=285 | 0.638 ± 3.0669 |
| Year 7 Week 24, n=183 | 0.938 ± 2.8158 |
| Year 7 Week 48, n=130 | 1.129 ± 3.0314 |
| Year 8 Week 24, n=52 | 1.280 ± 3.0707 |
| Year 8 Week 48, n=13 | 0.768 ± 3.0434 |
| Year 9 Week 24, n=6 | 0.028 ± 2.0182 |
| Year 9 Week 48, n=1 | -2.870 ± NA |
| Exit, n=624 | 0.573 ± 3.3274 |
| 8 Week follow-up, n=539 | 0.572 ± 3.1052 |
Immunoglobulin (Ig) parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 Ig parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ig G were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.
| g/L | Belimumab 10mg/kg IV |
|---|---|
| Year 1 Week 12, n=213 | -1.571 ± 2.2970 |
| Year 1 Week 24, n=709 | -1.963 ± 2.7334 |
| Year 1 Week 48, n=695 | -2.507 ± 3.1054 |
| Year 2 Week 24, n=482 | -3.058 ± 3.6147 |
| Year 2 Week 48, n=605 | -3.232 ± 3.7414 |
| Year 3 Week 24, n=143 | -3.453 ± 3.7073 |
| Year 3 Week 48, n=405 | -3.791 ± 4.0450 |
| Year 4 Week 24, n=146 | -3.839 ± 4.1411 |
| Year 4 Week 48, n=362 | -3.794 ± 3.8780 |
| Year 5 Week 24, n=111 | -4.356 ± 3.6399 |
| Year 5 Week 48, n=322 | -4.323 ± 4.0169 |
| Year 6 Week 24, n=71 | -5.111 ± 3.8846 |
| Year 6 Week 48, n=268 | -4.697 ± 3.9599 |
| Year 7 Week 24, n=50 | -4.803 ± 3.5908 |
| Year 7 Week 48, n=115 | -4.982 ± 4.0769 |
| Year 8 Week 24, n=18 | -6.016 ± 3.8450 |
| Year 8 Week 48, n=12 | -5.520 ± 5.1564 |
| Year 9 Week 48, n=1 | 0.710 ± NA |
| Exit, n=627 | -4.138 ± 4.0025 |
| 8 Week Follow up, n=543 | -4.325 ± 4.0246 |
Immunogenic response was analyzed using serum samples for anti-belimumab antibody measurements in MITT population. Categories of response are Negative, Transient Positive (+) means single + response that does not occur at the final assessment, and Persistent + means + response that occurs at least 2 consecutive assessments or a single result at the final assessment. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Belimumab 10mg/kg IV |
|---|---|
| Year 0-1 Negative, n=717 | 707 |
| Year 1-2 Negative, n=684 | 656 |
| Year 2-3 Negative, n=590 | 577 |
| Year 3-4, Negative, n=502 | 498 |
| Year 4-5 Negative, n=432 | 432 |
| Year 5-6 Negative, n=336 | 336 |
| Year 6-7 Negative, n=212 | 212 |
| Year 7-8 Negative, n=64 | 64 |
| Year 8 plus Negative, n=6 | 6 |
| Year 0-1 Transient +, n=717 | 10 |
| Year 1-2 Transient + n=684 | 18 |
| Year 2-3 Transient +, n=590 | 9 |
| Year 3-4 Transient +, n=502 | 4 |
| Year 4-5 Transient +, n=432 | 0 |
| Year 5-6 Transient +, n=336 | 0 |
| Year 6-7 Transient +, n=212 | 0 |
| Year 7-8 Transient +, n=64 | 0 |
| Year 8 plus Transient +, n=6 | 0 |
| Year 0-1 Persistent+,n=717 | 0 |
| Year 1-2 Persistent+,n=684 | 10 |
| Year 2-3 Persistent+,n=590 | 3 |
| Year 3-4 Persistent+,n=502 | 0 |
| Year 4-5 Persistent+,n=432 | 0 |
| Year 5-6 Persistent+,n=336 | 0 |
| Year 6-7 Persistent+,n=212 | 0 |
| Year 7-8 Persistent+,n=64 | 0 |
| Year 8 plus Persistent+,n=6 | 0 |
| Year 0-1 Unknown, n=717 | 0 |
| Year 1-2 Unknown, n=684 | 0 |
| Year 2-3 Unknown, n=590 | 1 |
| Year 3-4 Unknown, n=502 | 0 |
| Year 4-5 Unknown, n=432 | 0 |
| Year 5-6 Unknown, n=336 | 0 |
| Year 6-7 Unknown, n=212 | 0 |
| Year 7-8 Unknown, n=64 | 0 |
| Year 8 plus Unknown, n=6 | 0 |
Blood samples were collected to evaluate IgG levels at Baseline and at Weeks 12, 24 and 48 during Year 1. From Year 2-9, IgG was evaluated at Week 24 and 48 ; Exit visit and at follow-up visit (up to 8 weeks post last infusion). Number of participants with IgG immunoglobulin values below the LLN at each one year interval are presented. Baseline includes Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. If a participant had more than one response within a year, then the last response within the year interval (usually the Week 48 assessment) was summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Belimumab 10mg/kg IV |
|---|---|
| Baseline, n=735 | 6 |
| Any Time Post Baseline, n=735 | 64 |
| Year 0-1, n=735 | 22 |
| Year 1-2, n=701 | 24 |
| Year 2-3, n=620 | 22 |
| Year 3-4, n=514 | 19 |
| Year 4-5, n=442 | 15 |
| Year 5-6, n=345 | 10 |
| Year 6-7, n=219 | 8 |
| Year 7-8, n=65 | 2 |
| More than 8 Years, n=6 | 0 |
Participants who had improving SLE disease activity for at least 8 weeks, at the investigator's discretion, the steroid dose was reduced by reduction to 7.5 mg/day. If the participant continued to have stable or improving disease activity after 4 weeks on a reduced dose, then the investigator considered reducing the dose again. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. Number of participants with shifts from Baseline total daily dose category by visit is summarized.
| Participants | Participants With no Prednisone and Other Steroids at Baseline | Participants With Baseline Daily Dose of >0 to <=7.5 mg | Participants With Baseline Daily Dose of >7.5 to <=40 mg | Participants With Baseline Daily Dose of >40 mg |
|---|---|---|---|---|
| Total daily dose=0, Year 1, Week 24 | 40 | 5 | 1 | 0 |
| Total daily dose >0 to <=7.5, Year 1, Week 24 | 1 | 194 | 71 | 0 |
| Total daily dose >7.5 to <=40, Year 1, Week 24 | 2 | 18 | 376 | 1 |
| Total daily dose >40, Year 1, Week 24 | 0 | 0 | 1 | 0 |
| Total daily dose=0, Year 1, Week 48 | 40 | 13 | 13 | 0 |
| Total daily dose >0 to <=7.5, Year 1, Week 48 | 2 | 180 | 123 | 0 |
| Total daily dose >7.5 to <=40, Year 1, Week 48 | 0 | 19 | 301 | 1 |
| Total daily dose >40, Year 1, Week 48 | 1 | 0 | 4 | 0 |
| Total daily dose=0, Year 2, Week 24 | 39 | 19 | 20 | 0 |
| Total daily dose >0 to <=7.5, Year 2, Week 24 | 3 | 157 | 145 | 0 |
| Total daily dose >7.5 to <=40, Year 2, Week 24 | 0 | 25 | 237 | 1 |
| Total daily dose >40, Year 2, Week 24 | 0 | 0 | 5 | 0 |
| Total daily dose=0, Year 2, Week 48 | 36 | 24 | 21 | 0 |
| Total daily dose >0 to <=7.5, Year 2, Week 48 | 1 | 143 | 163 | 0 |
| Total daily dose >7.5 to <=40, Year 2, Week 48 | 1 | 26 | 195 | 1 |
| Total daily dose >40, Year 2, Week 48 | 0 | 0 | 1 | 0 |
| Total daily dose=0, Year 3, Week 24 | 33 | 19 | 25 | 0 |
| Total daily dose >0 to <=7.5, Year 3, Week 24 | 3 | 130 | 159 | 0 |
| Total daily dose >7.5 to <=40, Year 3, Week 24 | 1 | 27 | 157 | 1 |
| Total daily dose >40, Year 3, Week 24 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 3, Week 48 | 31 | 20 | 30 | 0 |
| Total daily dose >0 to <=7.5, Year 3, Week 48 | 3 | 122 | 127 | 0 |
| Total daily dose >7.5 to <=40, Year 3, Week 48 | 0 | 23 | 145 | 1 |
| Total daily dose >40, Year 3, Week 48 | 0 | 0 | 2 | 0 |
| Total daily dose=0, Year 4, Week 24 | 28 | 17 | 34 | 0 |
| Total daily dose >0 to <=7.5, Year 4, Week 24 | 3 | 110 | 134 | 0 |
| Total daily dose >7.5 to <=40, Year 4, Week 24 | 2 | 23 | 120 | 1 |
| Total daily dose >40, Year 4, Week 24 | 0 | 0 | 2 | 0 |
| Total daily dose=0, Year 4, Week 48 | 22 | 18 | 40 | 0 |
| Total daily dose >0 to <=7.5, Year 4, Week 48 | 3 | 100 | 129 | 1 |
| Total daily dose >7.5 to <=40, Year 4, Week 48 | 1 | 16 | 108 | 0 |
| Total daily dose >40, Year 4, Week 48 | 0 | 1 | 0 | 0 |
| Total daily dose=0, Year 5, Week 24 | 19 | 28 | 33 | 0 |
| Total daily dose >0 to <=7.5, Year 5, Week 24 | 3 | 84 | 124 | 1 |
| Total daily dose >7.5 to <=40, Year 5, Week 24 | 1 | 16 | 99 | 0 |
| Total daily dose >40, Year 5, Week 24 | 0 | 0 | 2 | 0 |
| Total daily dose=0, Year 5, Week 48 | 17 | 26 | 34 | 0 |
| Total daily dose >0 to <=7.5, Year 5, Week 48 | 1 | 75 | 119 | 1 |
| Total daily dose >7.5 to <=40, Year 5, Week 48 | 1 | 13 | 85 | 0 |
| Total daily dose >40, Year 5, Week 48 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 6, Week 24 | 10 | 25 | 33 | 0 |
| Total daily dose >0 to <=7.5, Year 6, Week 24 | 2 | 62 | 99 | 1 |
| Total daily dose >7.5 to <=40, Year 6, Week 24 | 0 | 10 | 76 | 0 |
| Total daily dose >40, Year 6, Week 24 | 0 | 0 | 2 | 0 |
| Total daily dose=0, Year 6, Week 48 | 10 | 24 | 35 | 0 |
| Total daily dose >0 to <=7.5, Year 6, Week 48 | 1 | 54 | 90 | 1 |
| Total daily dose >7.5 to <=40, Year 6, Week 48 | 0 | 11 | 68 | 0 |
| Total daily dose >40, Year 6, Week 48 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 7, Week 24 | 4 | 10 | 29 | 0 |
| Total daily dose >0 to <=7.5, Year 7, Week 24 | 0 | 41 | 64 | 1 |
| Total daily dose >7.5 to <=40, Year 7, Week 24 | 1 | 3 | 40 | 0 |
| Total daily dose >40, Year 7, Week 24 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 7, Week 48 | 4 | 3 | 24 | 0 |
| Total daily dose >0 to <=7.5, Year 7, Week 48 | 0 | 32 | 34 | 1 |
| Total daily dose >7.5 to <=40, Year 7, Week 48 | 0 | 6 | 29 | 0 |
| Total daily dose >40, Year 7, Week 48 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 8, Week 24 | 2 | 1 | 8 | 0 |
| Total daily dose >0 to <=7.5, Year 8, Week 24 | 0 | 13 | 15 | 1 |
| Total daily dose >7.5 to <=40, Year 8, Week 24 | 0 | 2 | 11 | 0 |
| Total daily dose >40, Year 8, Week 24 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 8, Week 48 | 1 | 0 | 5 | 0 |
| Total daily dose >0 to <=7.5, Year 8, Week 48 | 0 | 3 | 6 | 0 |
| Total daily dose >7.5 to <=40, Year 8, Week 48 | 0 | 2 | 1 | 0 |
| Total daily dose >40, Year 8, Week 48 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 9, Week 24 | 0 | 0 | 1 | 0 |
| Total daily dose >0 to <=7.5, Year 9, Week 24 | 0 | 1 | 3 | 0 |
| Total daily dose >7.5 to <=40, Year 9, Week 24 | 0 | 1 | 0 | 0 |
| Total daily dose >40, Year 9, Week 24 | 0 | 0 | 0 | 0 |
| Total daily dose=0, Year 9, Week 48 | 0 | 0 | 0 | 0 |
| Total daily dose >0 to <=7.5, Year 9, Week 48 | 0 | 1 | 4 | 0 |
| Total daily dose >7.5 to <=40, Year 9, Week 48 | 0 | 1 | 0 | 0 |
| Total daily dose >40, Year 9, Week 48 | 0 | 0 | 0 | 0 |
The SLICC/ACR Damage Index was assessed every 48 weeks and at the exit visit as a measure of disease activity. It was developed to assess the accumulated damage since the onset of the disease. The number of participants with worsening in their SLICC/ACR Damage Index score compared with Baseline have been presented. Worsening was defined as a change in score (post-Baseline visit score - Baseline score) \> 0. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. For years in which a participant was withdrawn from the study, the exit visit assessment was used in place of the Week 48 assessment for the year. This value was not carried forward through later years. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Belimumab 10mg/kg IV |
|---|---|
| Year 1,Week 48, n=716 | 39 |
| Year 2,Week 48, n=667 | 50 |
| Year 3,Week 48, n=580 | 56 |
| Year 4,Week 48, n=488 | 57 |
| Year 5,Week 48, n=423 | 51 |
| Year 6,Week 48, n=330 | 41 |
| Year 7,Week 48, n=213 | 28 |
| Year 8,Week 48, n=65 | 8 |
| Year 9,Week 48, n=6 | 0 |
Collected over On-treatment SAEs and non-serious adverse events (AEs) were collected from the start of investigational product and until 8 Weeks after the last infusion of trial medication (Approximately 8 years plus). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab 10mg/kg IV | 11/735 (1.5%) | 231/735 (31.4%) | 614/735 (83.5%) |
| Event | Belimumab 10mg/kg IV |
|---|---|
| Pneumonia bacterialInfections and infestations | 14/735 |
| CellulitisInfections and infestations | 12/735 |
| Lupus nephritisRenal and urinary disorders | 12/735 |
| PyrexiaGeneral disorders | 9/735 |
| Urinary tract infectionInfections and infestations | 9/735 |
| Urinary tract infection bacterialInfections and infestations | 9/735 |
| LeukopeniaBlood and lymphatic system disorders | 8/735 |
| PneumoniaInfections and infestations | 8/735 |
| AnaemiaBlood and lymphatic system disorders | 7/735 |
| AppendicitisInfections and infestations | 6/735 |
| Event | Belimumab 10mg/kg IV |
|---|---|
| HeadacheNervous system disorders | 205/735 |
| NasopharyngitisInfections and infestations | 155/735 |
| DiarrhoeaGastrointestinal disorders | 143/735 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 134/735 |
| InfluenzaInfections and infestations | 132/735 |
| CoughRespiratory, thoracic and mediastinal disorders | 120/735 |
| Back painMusculoskeletal and connective tissue disorders | 102/735 |
| Urinary tract infection bacterialInfections and infestations | 87/735 |
| Viral upper respiratory tract infectionInfections and infestations | 84/735 |
| Upper respiratory tract infectionInfections and infestations | 82/735 |
Modified Intention to Treat (MITT) includes all participants who were enrolled in BEL112234 and were treated with at least one dose of belimumab in the continuation study.
| Age, Continuous(Years) | Belimumab 10mg/kg IV |
|---|---|
| Mean | 37.2 ± 11.17 |
| Sex: Female, Male(Participants) | Belimumab 10mg/kg IV |
|---|---|
| Female | 695 |
| Male | 40 |
| Race/Ethnicity, Customized(Participants) | Belimumab 10mg/kg IV |
|---|---|
| Black or African American/African Heritage | 18 |
| American Indian or Alaska Native | 225 |
| East Asian Heritage | 118 |
| South Asian Heritage | 38 |
| Southeast Asian Heritage | 58 |
| Middle East/North African Heritage | 22 |
| White/Caucasian/European Heritage | 256 |
Showing the first 100 of 110 sites across 28 countries. Choose a country and city above to see the rest.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from May 2008 to primary completion in Dec 2016, 102 months.
Results were first posted in Jan 2018, 1 year 1 month after primary completion.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 102 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →
Human Genome Sciences Inc., a GSK Company →